Vitamin D and Calcium Supplement Attenuate Bone Loss among HIV-Infected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz: An Open-Label, Randomized Controlled Trial

被引:7
作者
Boontanondha, Patawee [1 ]
Nimitphong, Hataikarn [1 ]
Musikarat, Suchawadee [2 ]
Ragkho, Aschara [3 ]
Kiertiburanakul, Sasisopin [1 ]
机构
[1] Mahidol Univ, Fac Med Ramathibodi Hosp, Dept Med, Bangkok 10400, Thailand
[2] Mahidol Univ, Fac Med, Dept Diagnost & Therapeut Radiol, Ramathibodi Hosp, Bangkok 10400, Thailand
[3] Mahidol Univ, Fac Med, Dept Pathol, Ramathibodi Hosp, Bangkok 10400, Thailand
关键词
Bone loss; bone mineral density; calcium; HIV; tenofovir disoproxil fumarate; vitamin D; C VIRUS COINFECTION; ANTIRETROVIRAL THERAPY; MINERAL DENSITY; D DEFICIENCY; ABACAVIR-LAMIVUDINE; RISK-FACTORS; ADULTS; FUMARATE; FRACTURES; EFAVIRENZ;
D O I
10.2174/1570162X18666200106150806
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Antiretroviral therapy (ART), especially with tenofovir disoproxil fumarate (TDF), has been associated with accelerated bone turnover and leads to significant bone loss. Objective: We aimed to determine the effect of vitamin D-2 and calcium on bone mineral density (BMD) in HIV-infected patients receiving TDF/emtricitabine (FTC)/efavirenz (EFV). Methods: A prospective, open-label, randomized controlled study was conducted. Eligible patients were ART naive HIV individuals who initiated TDF/FTC/EFV. The study group received supplementation with vitamin D-2 and calcium carbonate, whereas the control group was administered only ART. The primary outcome was the percentage change in total hip BMD at week 24 compared with baseline. Results: A total of 18 patients were randomized (9 in each group). The mean (standard deviation; SD) total hip BMD significantly decreased from baseline in both groups, from 0.96 (0.14) g/cm(2) to 0.93 (0.13) g/cm(2) in the study group (p = 0.006) and from 0.87 (0.11) g/cm(2) to 0.84 (0.11) g/cm(2) in the control group (p = 0.004). The mean (SD) lumbar spine BMD significantly decreased from baseline in both groups, from 1.00 (0.13) g/cm(2) to 0.97 (0.13) g/cm(2) (p-0.004) in the study group and from 0.90 (0.09) g/cm(3) to 0.86 (0.08) g/cm(2) in the control group (p = 0.006). At week 24, the mean (SD) lumbar spine BMD was significantly greater in the study group than in the control group (p = 0.042). However, there were no significant differences in the percentage change of total hip, lumbar spine, and femoral neck BMD between both groups. No adverse events were reported. In conclusion, as early as 24 weeks after TDF initiation, a significant decline in BMD was detected. Conclusion: Vitamin D-2 and calcium supplements should be considered for HIV-infected patients receiving TDF/FTC/EFV in a resource-limited setting where there are limited ART options
引用
收藏
页码:52 / 62
页数:11
相关论文
共 36 条
  • [31] A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study
    Damronglerd, Pansachee
    Sukasem, Chonlaphat
    Thipmontree, Wilawan
    Puangpetch, Apichaya
    Kiertiburanakul, Sasisopin
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2015, 8 : 155 - 162
  • [33] Efficacy of vitamin D3 supplementation in reducing incidence of pulmonary tuberculosis and mortality among HIV-infected Tanzanian adults initiating antiretroviral therapy: study protocol for a randomized controlled trial
    Christopher R. Sudfeld
    Ferdinand Mugusi
    Said Aboud
    Tumaini J. Nagu
    Molin Wang
    Wafaie W. Fawzi
    Trials, 18
  • [34] Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial
    Pulido, Federico
    Ribera, Esteban
    Lagarde, Maria
    Perez-Valero, Ignacio
    Palacios, Rosario
    Iribarren, Jose A.
    Payeras, Antoni
    Domingo, Pere
    Sanz, Jose
    Cervero, Miguel
    Curran, Adrian
    Rodriguez-Gomez, Francisco J.
    Tellez, Maria J.
    Ryan, Pablo
    Barrufet, Pilar
    Knobel, Hernando
    Rivero, Antonio
    Alejos, Belen
    Yllescas, Maria
    Arribas, Jose R.
    CLINICAL INFECTIOUS DISEASES, 2017, 65 (12) : 2112 - 2118
  • [35] Efficacy and safety of 400 mg efavirenz versus standard 600 mg dose when taken with tenofovir and lamivudine combination in Indian adult patients with HIV-1 infection: An open-label, interventional, randomized, non-inferiority trial
    Dravid, Ameet
    Pilawan, Anant S. S.
    Anuradha, S.
    Morkar, Dnyanesh N.
    Ramapuram, John T.
    Madhukarrao, Kulkarni Milind
    Naik, K. Sunil
    Bhrusundi, Milind
    Raveendra, K. R.
    Nageswaramma, Siddabathuni
    Kulkarni, Vinay
    MEDICINE, 2022, 101 (48) : E31982
  • [36] Effect of maternal vitamin D3 supplementation on maternal health, birth outcomes, and infant growth among HIV-infected Tanzanian pregnant women: study protocol for a randomized controlled trial
    Sudfeld, Christopher R.
    Manji, Karim P.
    Duggan, Christopher P.
    Aboud, Said
    Muhihi, Alfa
    Sando, David M.
    Al-Beity, Fadhlun M. Alwy
    Wang, Molin
    Fawzi, Wafaie W.
    TRIALS, 2017, 18